# Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05204862/  
OnCo record `nct05204862` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TU2218 in advanced solid tumours, run by TiumBio Co., Ltd., now recruiting.

## Summary

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05204862 by TiumBio Co., Ltd., with 240 participants planned, started 2021-12-02 and due to reach its primary completion in 2026-06-30. Interventions recorded: TU2218 and Anti-PD-1 antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05204862
- Phase: 1/2
- Setting: A Phase 1/2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Inhibitor, Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- Sponsor: TiumBio Co., Ltd.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT05204862: https://clinicaltrials.gov/study/NCT05204862

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [TiumBio](https://onco.cc/companies/tiumbio/)

---
JSON: https://onco.cc/api/v1/entities/nct05204862.json